Hyperphosphatemia – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 8 PAGES: 58

More Info
									           Hyperphosphatemia – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1997IDB
                                                                                              Publication Date: April 2012




Hyperphosphatemia – Pipeline Review, H1 2012                                                  GMDHC1997IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Hyperphosphatemia – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 5
Introduction......................................................................................................................................................................................... 6
    Global Markets Direct Report Coverage ........................................................................................................................................ 6
Hyperphosphatemia Overview ........................................................................................................................................................... 7
Therapeutics Development................................................................................................................................................................. 8
    An Overview of Pipeline Products for Hyperphosphatemia ........................................................................................................... 8
Hyperphosphatemia Therapeutics under Development by Companies............................................................................................ 10
Late Stage Products ......................................................................................................................................................................... 12
    Comparative Analysis .................................................................................................................................................................. 12
Mid Clinical Stage Products.............................................................................................................................................................. 13
    Comparative Analysis .................................................................................................................................................................. 13
Early Clinical Stage Products ........................................................................................................................................................... 14
    Comparative Analysis .................................................................................................................................................................. 14
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 15
    Comparative Analysis .................................................................................................................................................................. 15
Hyperphosphatemia Therapeutics – Products under Development by Companies.......................................................................... 16
Companies Involved in Hyperphosphatemia Therapeutics Development ........................................................................................ 17
    Amgen Inc. .................................................................................................................................................................................. 17
    Novartis AG ................................................................................................................................................................................. 18
    Mitsubishi Tanabe Pharma Corporation ...................................................................................................................................... 19
    Panion & Bf Biotech Inc. .............................................................................................................................................................. 20
    Spectrum Pharmaceuticals, Inc. .................................................................................................................................................. 21
    Cytochroma Inc. .......................................................................................................................................................................... 22
    Vifor Pharma Ltd.......................................................................................................................................................................... 23
    Medice Arzneimittel Putter GmbH & Co. KG ............................................................................................................................... 24
Hyperphosphatemia – Therapeutics Assessment ............................................................................................................................ 25
    Assessment by Monotherapy Products ....................................................................................................................................... 25
    Assessment by Route of Administration ...................................................................................................................................... 26
    Assessment by Molecule Type .................................................................................................................................................... 28
Drug Profiles..................................................................................................................................................................................... 30
    SBR759 - Drug Profile ................................................................................................................................................................. 30
         Product Description................................................................................................................................................................. 30
         Mechanism of Action ............................................................................................................................................................... 30
         R&D Progress ......................................................................................................................................................................... 30
    MCI-196 - Drug Profile ................................................................................................................................................................. 32
         Product Description................................................................................................................................................................. 32
         Mechanism of Action ............................................................................................................................................................... 32
         R&D Progress ......................................................................................................................................................................... 32
    Bixalomer - Drug Profile .............................................................................................................................................................. 34
         Product Description................................................................................................................................................................. 34



Hyperphosphatemia – Pipeline Review, H1 2012                                                                                                       GMDHC1997IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Hyperphosphatemia – Pipeline Review, H1 2012




        Mechanism of Action ............................................................................................................................................................... 34
        R&D Progress ......................................................................................................................................................................... 34
    Zerenex - Drug Profile ................................................................................................................................................................. 36
        Product Description................................................................................................................................................................. 36
        Mechanism of Action ............................................................................................................................................................... 36
        R&D Progress ......................................................................................................................................................................... 36
    RenaZorb - Drug Profile .............................................................................................................................................................. 39
        Product Description................................................................................................................................................................. 39
        Mechanism of Action ............................................................................................................................................................... 39
        R&D Progress ......................................................................................................................................................................... 39
    PA21 - Drug Profile...................................................................................................................................................................... 40
        Product Description................................................................................................................................................................. 40
        Mechanism of Action ............................................................................................................................................................... 40
        R&D Progress ......................................................................................................................................................................... 40
    Phosphate Management Program - Drug Profile ......................................................................................................................... 42
        Product Description................................................................................................................................................................. 42
        Mechanism of Action ............................................................................................................................................................... 42
        R&D Progress ......................................................................................................................................................................... 42
    Nicotinamide - Drug Profile .......................................................................................................................................................... 43
        Product Description................................................................................................................................................................. 43
        Mechanism of Action ............................................................................................................................................................... 43
        R&D Progress ......................................................................................................................................................................... 43
    PT20 - Drug Profile ...................................................................................................................................................................... 44
        Product Description................................................................................................................................................................. 44
        Mechanism of Action ......................................................................................................................................................
								
To top